Robert T Streeper1, Elzbieta Izbicka2, Christopher Louden3. 1. New Frontier Labs L.L.C., San Antonio, TX, U.S.A. 2. New Frontier Labs L.L.C., San Antonio, TX, U.S.A. eizbicka.g4@gmail.com. 3. Louden Consulting, Bandera, TX, U.S.A.
Abstract
BACKGROUND/AIM: Insulin resistance (IR) is linked to increased risk of cardiovascular disease and cancer. We examined safety and efficacy of the natural product diethyl azelate (DEA) in overweight males with a varying degree of IR. PATIENTS AND METHODS: Seventeen subjects [age 18-42, hemoglobin A1c (A1c) of 5.2-6.2%] received orally 1 mg/kg DEA daily for 21 days. Blood plasma glucose, insulin and lipid levels were assessed before and after treatment. RESULTS: DEA was well tolerated without hypoglycemia or adverse effects except transient diarrhea (n=1). DEA significantly reduced fasting glucose by 6.06 mg/dl (n=8) and insulin by 37.8% (n=8) in subjects with IR and/or A1c ≥5.6%. Furthermore, it improved cholesterol/HDL, LDL/HDL, and non-cholesterol HDL/HDL by 5.4, 6.5, and 6.6%, respectively in all subjects, and by 8.0, 9.8, and 9.8%, respectively in 9 subjects with A1c ≥5.6%. CONCLUSION: DEA efficacy correlates with the degree of IR. DEA holds promise as a novel treatment for the management of IR. Copyright
BACKGROUND/AIM: Insulin resistance (IR) is linked to increased risk of cardiovascular disease and cancer. We examined safety and efficacy of the natural product diethyl azelate (DEA) in overweight males with a varying degree of IR. PATIENTS AND METHODS: Seventeen subjects [age 18-42, hemoglobin A1c (A1c) of 5.2-6.2%] received orally 1 mg/kg DEA daily for 21 days. Blood plasma glucose, insulin and lipid levels were assessed before and after treatment. RESULTS:DEA was well tolerated without hypoglycemia or adverse effects except transient diarrhea (n=1). DEA significantly reduced fasting glucose by 6.06 mg/dl (n=8) and insulin by 37.8% (n=8) in subjects with IR and/or A1c ≥5.6%. Furthermore, it improved cholesterol/HDL, LDL/HDL, and non-cholesterol HDL/HDL by 5.4, 6.5, and 6.6%, respectively in all subjects, and by 8.0, 9.8, and 9.8%, respectively in 9 subjects with A1c ≥5.6%. CONCLUSION:DEA efficacy correlates with the degree of IR. DEA holds promise as a novel treatment for the management of IR. Copyright
Authors: Guenther Boden; Carol Homko; Carlos A Barrero; T Peter Stein; Xinhua Chen; Peter Cheung; Chiara Fecchio; Sarah Koller; Salim Merali Journal: Sci Transl Med Date: 2015-09-09 Impact factor: 17.956
Authors: Adrian V Hernandez; Vinay Pasupuleti; Vicente A Benites-Zapata; Priyaleela Thota; Abhishek Deshpande; Faustino R Perez-Lopez Journal: Eur J Cancer Date: 2015-11-18 Impact factor: 9.162
Authors: Paolo Brambilla; Elisa La Valle; Rosanna Falbo; Giuseppe Limonta; Stefano Signorini; Fabrizio Cappellini; Paolo Mocarelli Journal: Diabetes Care Date: 2011-04-15 Impact factor: 19.112